3 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 2 Phase 1, 2 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow copper dotatate CU-64: new trials by email Literature Review of copper dotatate CU-64 trials Research Report on copper dotatate CU-64
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography - Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm | Phase 1 | Recruiting | Emory University | 15 | 2025-10-14 | 2026-03-02 |
| Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution - Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Phase 3 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 166 | 2025-06-12 | 2026-09-16 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB - Metastatic Neuroendocrine Prostate Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 31 | 2024-07-29 | 2026-11-17 |
| Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms 18F-FDG, 64Cu-Dotatate - GEP-NET, Neuroendocrine Tumors | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 200 | 2023-01-17 | 2023-11-22 |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Lutetium [177Lu] oxodotreotide/dotatate - Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma | Phase 2 | Active not recruiting | Advanced Accelerator Applications | 11 | 2022-08-31 | 2026-02-12 |
| Spanish Series of Patients Treated With the Radionuclide Lutetium177 Lutetium [177Lu] oxodotreotide/dotatate - Neuroendocrine Tumors, Intestinal Neoplasms | Recruiting | Sociedad EspaƱola de Medicina Nuclear e Imagen Molecular | 5000 | 2021-05-10 | 2022-12-23 | |
| Somatostatin Receptor Imaging in Cardiac Sarcoidosis Cu-64 DOTATATE - Cardiac Sarcoidosis | Withdrawn | Copenhagen University Hospital, Rigshospitalet | 2016-06-01 | 2020-10-14 | ||
| Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate [177Lu] DOTA-TATE - Neuroendocrine Tumors | Not applicable | Completed | Instituto Nacional de Cancerologia, Columbia | 39 | 2013-11-01 | 2019-11-14 |
Gastro-enteropancreatic neuroendocrine tumor (4) · Neuroendocrine Tumors (4) · Carcinoma, Neuroendocrine (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1)
Copenhagen University Hospital, Rigshospitalet (2) · Advanced Accelerator Applications (1) · Emory University (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · Instituto Nacional de Cancerologia, Columbia (1) · Novartis Pharmaceuticals (1) · Sociedad EspaƱola de Medicina Nuclear e Imagen Molecular (1)
Spain (4) · France (3) · United States (3) · Denmark (2) · United Kingdom (2) · Colombia (1) · Germany (1) · Poland (1)
Andreas Kjaer, MD (1) · Eric Baudin Baudin, M.D., Ph.D. (1) · Mercedes Dr Mitjavila Casanovas, MD-PhD (1) · Pretesh Patel, MD (1) · Rasmus S Ripa, MD, DMSc (1)
2023 (1), P30CA138292 (1)